This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this project is to determine: 1) The predictive value of islet cell antibodies and insulin autoantibodies in identifying individuals with beta cell dysfunction among non-diabetics. 2) The pattern of change in beta cell function over time in individuals positive for one or more of the above immunologic markers. 3) Whether one treatment is superior over another in the management of type 1.5 diabetes. Type 1.5 diabetes looks like type 2 but has the autoantibodies commonly seen in type 1. Compared to classic type 2 patients, type 1.5 diabetes has a more rapid decline in beta cell function, fails sulfonylurea therapy and requires insulin therapy earlier. The intervention study under purpose #3 compares rosiglitazone to glyburide to determine which study drug results in better preservation of beta cell function in patients with type 1.5 diabetes.
Showing the most recent 10 out of 563 publications
